To address the impact of IDH1 mutation on anti-tumor T cell activity, we examined how IDH1 and IDH1R132H transfection impacted GL26 progression in DC vaccine-treated syngeneic (C57BL/6; B6) hosts. The gene discussed is IDH1; the disease is neoplasm.